SonoNeu Exits Stealth with $41M to Turn Sound into Medicine

PALO ALTO, CA – April 07, 2026 – A new era of non-invasive medicine may be on the horizon, powered not by scalpels or pills, but by sound. Today, biotechnology firm SonoNeu emerged from stealth mode, revealing its central role in a major U.S. government-backed initiative to advance a revolutionary technology called sonogenetics. The project, led by the Salk Institute for Biological Studies, has been awarded up to $41.3 million by the Advanced Research Projects Agency for Health (ARPA-H), signaling a significant bet on a future of drug-free, precision therapies.

SonoNeu, a spin-out from the Salk Institute, will serve as the commercial engine for a multi-institution collaboration aimed at moving sonogenetics from the laboratory to the clinic. The technology, discovered by SonoNeu co-founder and Salk scientist Sreekanth Chalasani, PhD, uses focused ultrasound to precisely control genetically modified cells. The initial target is peripheral neuropathy, a debilitating condition that causes pain and numbness in millions, with a long-term vision that extends to brain disorders and even brain-computer interfaces.

The Science of Sound Control

At its core, sonogenetics is a novel form of cellular control that offers the deep-tissue reach of ultrasound with the specificity of genetic engineering. The process is conceptually similar to optogenetics, which uses light to control neurons, but it overcomes light's primary limitation: its inability to penetrate deep into the body without invasive fiber optics. Ultrasound, by contrast, can be focused non-invasively on specific points deep within tissues.

The technique works by introducing a gene into target cells—for example, specific neurons—that causes them to produce a special mechanosensitive protein. These proteins, which act as ion channels in the cell membrane, are engineered to be responsive to the mechanical pressure of ultrasound waves. When ultrasound is applied, these channels open, allowing ions to flow into the cell and altering its activity—either exciting or inhibiting it. Early research by Professor Chalasani identified proteins like TRP-4 in worms, and later hsTRPA1, which proved effective in mammalian cells.

“This award is a major step toward a long-held goal - a drug-free way to deliver therapy exactly where it’s needed and only when it’s needed,” said Professor Chalasani, who is also the lead principal investigator for the ARPA-H award. “We are building a platform that pairs engineered ultrasound-sensitive proteins with wearable ultrasound technology.”

This approach promises a level of spatial and temporal precision that current pharmaceuticals, which act systemically, cannot match. A therapy could be activated exactly where it is needed in the body and turned off the moment it is not, potentially minimizing side effects and revolutionizing treatment for conditions caused by localized cellular dysfunction.

A High-Stakes Bet on Health Innovation

The up to $41.3 million award from ARPA-H, a federal agency created to fund high-risk, high-reward biomedical research, is a powerful endorsement of sonogenetics' potential. ARPA-H operates on a model similar to DARPA, the defense research agency responsible for breakthroughs like the internet and GPS, aiming to accelerate radical innovations that might struggle to find funding through traditional channels. SonoNeu itself will receive up to $5.2 million as part of the award to coordinate the translation of the research into therapeutic candidates.

The project is a testament to the power of collaborative science. SonoNeu and the Salk Institute are joined by a consortium of six other leading U.S. institutions, each contributing a critical piece of the puzzle. The team includes:

• Scripps Research: A team led by Nobel Laureate Ardem Patapoutian, whose foundational work on mechanosensitive channels provides unparalleled expertise in discovering and engineering the core proteins that make sonogenetics possible.
• Massachusetts Institute of Technology (MIT): A team led by Xuanhe Zhao will focus on developing the next-generation wearable ultrasound delivery systems needed to activate the engineered cells in animals and, eventually, humans.
• Duke University: A team led by Aravind Asokan will develop the targeted vectors—often modified viruses—required to safely and effectively deliver the genes for the ultrasound-sensitive proteins to the correct cells in the body.

Additional teams from the University of Manitoba, UC San Diego, and the California Medical Innovations Institute will contribute expertise in nerve repair pathways, preclinical validation, and translational assessments, creating an end-to-end pipeline from basic science to FDA evaluation.

Targeting a New Frontier in Medicine

The initial clinical target for this powerful collaboration is peripheral neuropathy, a condition affecting an estimated 20 million people in the U.S. alone. Often a complication of diabetes, chemotherapy, or injury, it results from damage to the nerves outside the brain and spinal cord, leading to chronic pain, numbness, and weakness. Current treatments, including pain relievers, antidepressants, and anti-seizure medications like gabapentin, primarily manage symptoms and often come with significant side effects and limited efficacy. They do not address the underlying nerve damage.

Sonogenetics offers a radically different approach. One potential outcome, as Professor Chalasani noted, is to “promote nerve repair and the relief of pain.” By precisely targeting and activating cellular pathways involved in nerve regeneration, the technology could offer the first therapy that actively repairs the damage, rather than just masking the pain. This represents a massive unmet need and a significant market opportunity.

Beyond Neuropathy: The Future of Neuro-Modulation

While neuropathy is the first challenge, the platform's potential is far broader. The research team envisions a future where sonogenetics provides non-invasive treatments for a host of central nervous system disorders. For instance, it could offer a safer alternative to deep-brain stimulation (DBS) for Parkinson's disease, which currently requires implanting electrodes deep within the brain to control tremors.

Perhaps most futuristically, sonogenetics could provide a non-invasive pathway for two-way communication with the brain, a holy grail in the field of brain-computer interfaces (BCIs). Companies like Neuralink are pursuing this goal with surgically implanted micro-electrode arrays. Sonogenetics holds the promise of achieving similar functionality—reading from and writing to specific neural circuits—without the need for a single incision, by delivering mechanosensitive channels safely and activating them with highly focused sound waves. The journey from treating nerve pain in the foot to communicating with the brain is long and fraught with scientific and regulatory hurdles, but with this major federal backing, the first critical steps are now being taken.